| Year |
Citation |
Score |
| 2008 |
McCulloch M, Zhou X, Xu Y, Brunell S, Spear L. Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 863: 258-265. PMID 18258497 DOI: 10.1016/j.jchromb.2008.01.020 |
0.374 |
|
| 2006 |
Brunell SC, Spear LP. Effects of acute ethanol or amphetamine administration on the acoustic startle response and prepulse inhibition in adolescent and adult rats. Psychopharmacology. 186: 579-86. PMID 16758242 DOI: 10.1007/S00213-006-0380-9 |
0.642 |
|
| 2005 |
Doremus TL, Brunell SC, Rajendran P, Spear LP. Factors influencing elevated ethanol consumption in adolescent relative to adult rats. Alcoholism, Clinical and Experimental Research. 29: 1796-808. PMID 16269909 DOI: 10.1097/01.Alc.0000183007.65998.Aa |
0.646 |
|
| 2005 |
Brunell SC, Spear LP. Effect of stress on the voluntary intake of a sweetened ethanol solution in pair-housed adolescent and adult rats. Alcoholism, Clinical and Experimental Research. 29: 1641-53. PMID 16205364 DOI: 10.1097/01.Alc.0000179382.64752.13 |
0.652 |
|
| 2003 |
Doremus TL, Brunell SC, Varlinskaya EI, Spear LP. Anxiogenic effects during withdrawal from acute ethanol in adolescent and adult rats. Pharmacology, Biochemistry, and Behavior. 75: 411-8. PMID 12873633 DOI: 10.1016/S0091-3057(03)00134-5 |
0.649 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Brian Cross L, Brunell SC. Potential use of GLP-1 receptor agonists in type 2 diabetes mellitus American Journal of Pharmacy Benefits. 5: 139-150. |
0.083 |
|
| 2013 |
La Rue S, Brunell SC, De Young MB, Hieronymus LB, Bezarro E, Chen S. Optimizing the clinical use of the GLP-1 receptor agonist exenatide once weekly Diabetes Spectrum. 26: 46-52. DOI: 10.2337/diaspect.26.1.46 |
0.073 |
|
| 2012 |
Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgraduate Medicine. 124: 21-32. PMID 22913891 DOI: 10.3810/pgm.2012.07.2567 |
0.071 |
|
| 2012 |
Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 18: 227-37. PMID 22446132 DOI: 10.4158/EP11306.OR |
0.054 |
|
| 2014 |
Røsjø H, Vaahersalo J, Hagve TA, Pettilá V, Kurola J, Omland T, Brunell SC, Lund V, Tuominen P, Johansson S, Perkola P, Kumpulainen E, Suvela M, Hirvonen S, Kauppinen S, et al. Prognostic value of high-sensitivity troponin T levels in patients with ventricular arrhythmias and out-of-hospital cardiac arrest: Data from the prospective FINNRESUSCI study Critical Care. 18. DOI: 10.1186/s13054-014-0605-y |
0.045 |
|
| 2014 |
Herrmann K, Shan K, Brunell SC, Chen S. Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 20: 1070-5. PMID 25100363 DOI: 10.4158/EP13477.OR |
0.031 |
|
| 2013 |
Grimm M, Li Y, Brunell SC, Blase E. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgraduate Medicine. 125: 101-8. PMID 24113668 DOI: 10.3810/pgm.2013.09.2704 |
0.03 |
|
| 2016 |
Herrmann K, Brunell SC, Li Y, Zhou M, Maggs DG. Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials. Advances in Therapy. PMID 27071768 DOI: 10.1007/s12325-016-0326-5 |
0.029 |
|
| 2012 |
Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. International Journal of Clinical Practice. 66: 1021-32. PMID 22925173 DOI: 10.1111/j.1742-1241.2012.03006.x |
0.029 |
|
| 2012 |
Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. Journal of Medical Economics. 15: 6-13. PMID 22793669 DOI: 10.3111/13696998.2012.708691 |
0.028 |
|
| 2012 |
Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Postgraduate Medicine. 124: 33-40. PMID 22913892 DOI: 10.3810/pgm.2012.07.2568 |
0.026 |
|
| 2016 |
Sheu WH, Brunell SC, Blase E. Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis. Diabetes Research and Clinical Practice. PMID 26827116 DOI: 10.1016/j.diabres.2015.12.004 |
0.02 |
|
| Hide low-probability matches. |